Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer

Дата публикации: 28-07-2026 00:00:00

This randomized trial assesses the effect of ivonescimab added to chemotherapy on overall survival among patients with EGFR-variant non–small cell lung cancer (NSCLC) who had disease progression with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors	0	4.57	01-09-2023
2	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026
3	PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression	0	15.58	01-07-2026
4	Disitamab Vedotin Plus Tislelizumab in Non–Muscle-Invasive Bladder Cancer	0	13.81	08-10-2026
5	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
6	Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer	0	8.64	01-08-2026
7	Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer	0	10.75	16-10-2026
8	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
9	Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?	0	10.94	17-09-2026
10	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10. Источник: jamanetwork.com.